China Resources Pharmaceutical Group Ltd (3320.HK)
Company Info
Highlights
HK$30.78B
8.75
1.01
HK$4.61 - HK$7.11
HK$6.78
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
Loading data...
Returns By Period
China Resources Pharmaceutical Group Ltd (3320.HK) returned -13.58% year-to-date (YTD) and -12.77% over the past 12 months.
3320.HK
-13.58%
-1.01%
-13.88%
-12.77%
3.91%
N/A
^GSPC (Benchmark)
-3.77%
7.44%
-5.60%
8.37%
14.12%
10.46%
Monthly Returns
The table below presents the monthly returns of 3320.HK, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | -7.94% | 1.53% | -4.53% | -3.16% | 0.00% | -13.58% | |||||||
| 2024 | -7.21% | 11.34% | -5.66% | 1.60% | 13.97% | 3.03% | -7.77% | 3.00% | 11.21% | -8.49% | -4.55% | 8.00% | 15.88% |
| 2023 | -6.65% | 9.32% | -3.57% | 25.08% | -3.47% | -7.23% | -11.29% | -13.39% | -0.76% | -6.54% | 0.41% | 5.12% | -17.08% |
| 2022 | 7.04% | 1.58% | 5.70% | 2.20% | 4.08% | 27.43% | -11.82% | 14.47% | 0.19% | -1.67% | 20.75% | -1.25% | 84.72% |
| 2021 | 2.51% | 21.32% | -2.02% | 8.25% | 6.09% | -11.16% | -14.05% | -2.64% | -5.43% | -2.09% | -9.60% | 4.72% | -8.81% |
| 2020 | -9.68% | 3.83% | -31.42% | 5.38% | -13.88% | 11.43% | -1.57% | -0.23% | -9.34% | -2.76% | 8.27% | -5.01% | -42.09% |
| 2019 | 9.00% | -5.57% | 5.51% | 0.54% | -8.24% | -12.86% | -2.72% | -5.48% | -9.26% | -1.36% | -5.66% | 5.70% | -28.35% |
| 2018 | 1.78% | 2.52% | 4.17% | -1.27% | 11.97% | -9.80% | 5.16% | 9.98% | -1.11% | -7.41% | 0.00% | -11.13% | 2.00% |
| 2017 | -3.54% | -0.35% | 7.97% | 0.88% | 0.24% | 7.26% | -3.90% | 3.52% | -4.33% | 2.37% | 9.05% | -2.32% | 16.83% |
| 2016 | 0.11% | -4.66% | 1.74% | -2.89% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of 3320.HK is 49, indicating average performance compared to other stocks on our website. Here’s a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for China Resources Pharmaceutical Group Ltd (3320.HK) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Loading data...
Dividends
Dividend History
China Resources Pharmaceutical Group Ltd provided a 5.32% dividend yield over the last twelve months, with an annual payout of HK$0.26 per share. The company has been increasing its dividends for 3 consecutive years.
| Period | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Dividend | HK$0.26 | HK$0.26 | HK$0.16 | HK$0.15 | HK$0.12 | HK$0.22 | HK$0.13 | HK$0.11 | HK$0.09 |
Dividend yield | 5.32% | 4.59% | 3.12% | 2.37% | 3.38% | 5.53% | 1.80% | 1.08% | 0.89% |
Monthly Dividends
The table displays the monthly dividend distributions for China Resources Pharmaceutical Group Ltd. The dividends shown in the table have been adjusted to account for any splits that may have occurred.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | |||||||
| 2024 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.17 | HK$0.00 | HK$0.00 | HK$0.09 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.26 |
| 2023 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.16 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.16 |
| 2022 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.15 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.15 |
| 2021 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.12 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.12 |
| 2020 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.22 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.22 |
| 2019 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.13 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.13 |
| 2018 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.11 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.11 |
| 2017 | HK$0.09 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.09 |
Dividend Yield & Payout
Dividend Yield
China Resources Pharmaceutical Group Ltd has a dividend yield of 5.32%, which is quite average when compared to the overall market.
Payout Ratio
China Resources Pharmaceutical Group Ltd has a payout ratio of 44.55%, which is quite average when compared to the overall market. This suggests that China Resources Pharmaceutical Group Ltd strikes a balance between reinvesting profits for growth and paying dividends to shareholders.
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading data...
Worst Drawdowns
The table below displays the maximum drawdowns of the China Resources Pharmaceutical Group Ltd. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the China Resources Pharmaceutical Group Ltd was 72.81%, occurring on Dec 20, 2021. The portfolio has not yet recovered.
The current China Resources Pharmaceutical Group Ltd drawdown is 53.58%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -72.81% | Sep 4, 2018 | 813 | Dec 20, 2021 | — | — | — |
| -19.23% | Apr 9, 2018 | 60 | Jul 5, 2018 | 39 | Aug 29, 2018 | 99 |
| -10.08% | Jul 4, 2017 | 29 | Aug 11, 2017 | 66 | Nov 16, 2017 | 95 |
| -8.84% | Jan 22, 2018 | 15 | Feb 9, 2018 | 5 | Feb 20, 2018 | 20 |
| -8.72% | Nov 17, 2017 | 14 | Dec 6, 2017 | 19 | Jan 5, 2018 | 33 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading data...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of China Resources Pharmaceutical Group Ltd over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Earnings Per Share
The chart presents the Earnings Per Share (EPS) performance of China Resources Pharmaceutical Group Ltd, comparing actual results with analytics estimates. In the past quarter, the company did not meet analyst expectations for EPS, resulting in a surprise of -10.4%.
Valuation
The Valuation section provides an overview of how China Resources Pharmaceutical Group Ltd is priced in the market compared to other companies in the Drug Manufacturers - Specialty & Generic industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for 3320.HK, comparing it with other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, 3320.HK has a P/E ratio of 8.8. This P/E ratio is considered low compared to industry peers, which may suggest that the stock is undervalued or that the company has weaker growth prospects.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for 3320.HK compared to other companies in the Drug Manufacturers - Specialty & Generic industry. 3320.HK currently has a PEG ratio of 1.0. This PEG ratio is close to the industry average, suggesting the stock’s valuation is balanced against its growth outlook.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for 3320.HK relative to other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, 3320.HK has a P/S ratio of 0.1. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for 3320.HK in comparison with other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, 3320.HK has a P/B value of 0.6. This P/B ratio is low compared to industry peers. It might indicate the stock is undervalued or that the company’s assets are not expected to generate strong returns.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |